Project Grant R21AI193455
- This Project Grant award of $373,090 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Yale University is focused on developing "molecular degraders of extracellular proteins." The research aims to (1) create improved degradation molecules with better drug-like properties, (2) establish a high-throughput assay to rapidly evaluate degradation molecule candidates, and (3) demonstrate the efficacy of these...
- This $4,164,187 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop antigen-directed therapies for autoantibody associated neuroinflammatory diseases. The project aims to facilitate the discovery of autoantibodies directed to cell surface antigens, characterize their specificity, and generate recombinant human...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $164,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albany Medical College. The grant supports research to identify and characterize additional conformer-specific anti-I-A monoclonal antibodies (mAbs) to study the structure and function of MHC class II molecules, which are important for T cell-mediated immune responses. The research aims to address limitations in existing...
- This $858,186 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports a research project titled "Decoding T Cell Clonotypes, Biology and Predictive Biomarkers Associated with Immune Checkpoint Myocarditis." The project aims to investigate the mechanisms underlying immune-related myocarditis, a potentially fatal adverse event associated with immune checkpoint inhibitor cancer therapies. Using...
- This Project Grant award, valued at $416,276.00 and provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to investigate factors that modulate the Fc-mediated immune responses of antibodies. The research seeks to increase the potency of protection resulting from antibodies requiring Fc functions for influenza virus or antibodies against Streptococcus pneumoniae. The University...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $197,640 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on July 16, 2025. This grant supports research to investigate the contribution of a novel monocyte transcriptional state, termed Monocyte Substate 1 (MS1), to sepsis immunopathogenesis and patient heterogeneity. The project will...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $197,640 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, awarded on August 1, 2025, will support research to determine the drivers of immune checkpoint inhibitor-related myocarditis (IRMYOCARDITIS) and develop therapeutic strategies to modulate interactions between T cells and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $101,982 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Massachusetts Medical School (UMMS) to conduct research on the "Temporal Regulation of mRNA Biogenesis in Immune Responses." This 21-month project, running from May 2025 to February 2027, seeks to uncover mechanistic insights into the regulation and impact of stimulus-induced immune mRNA...
- This $979,138 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a multivariate machine learning analysis of blood-based RNA expression profiles to distinguish relapsing-remitting and progressive forms of multiple sclerosis. The award, with a performance period from August 1, 2025 to July 31, 2027, was granted to Decode Health, Inc. to advance...
- The University of New Mexico received a $221,888 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to explore mechanisms for inducing apoptosis in Th17 cells. The project aims to target the IRE1 and STAT3 pathways to diminish the pathogenic function of Th17 cells, which play a role in inflammatory and autoimmune diseases despite their function in host defense. The award period is from January 22, 2025 to December...
This $251,375 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Yale University aims to identify immune mechanisms driving seronegative myasthenia gravis (SNMG), a form of the autoimmune disease myasthenia gravis where the underlying autoantibodies are unknown. The researchers will utilize high-throughput autoantibody discovery technologies to screen large human antigen libraries and identify potential new antigens associated with SNMG. This work seeks to address the lack of understanding around SNMG disease mechanisms, which has impacted treatment and clinical trial options for these patients. The award commenced on September 2, 2025 and is scheduled for completion on August 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $251.4k | 9/2/25 |